FindTrial
Sign In

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT02354612
Enrollment
Unknown
Registered
2015-02-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumors

Brief summary

Open-label, continuation study

Detailed description

This is a multicenter, open-label, non-randomized, study of TRC105 in patients that have completed a previous TRC105 study and are judged by the investigator to have the potential to benefit from continued TRC105 therapy.

Interventions

DRUGTRC105
DRUGBevacizumab

companion therapy selection depends on companion therapy used in the parent study

DRUGAxitinib

companion therapy selection depends on companion therapy used in the parent study

DRUGPazopanib

companion therapy selection depends on companion therapy used in the parent study

DRUGCapecitabine

companion therapy selection depends on companion therapy used in the parent study

Sponsors

Tracon Pharmaceuticals Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Participation in a TRACON Pharmaceuticals sponsored parent TRC105 study and, thought to have potential to derive clinical benefit from continued treatment with TRC105 in the opinion of the parent study investigator. * Willing and able to consent for self to participate in study * Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. * 18 years of age or older * ability to begin TRC105 dosing on this protocol within 6 weeks from the subjects last dose of TRC105 in the parent TRC105 study

Exclusion criteria

* Any clinical event that would make TRC105 therapy inappropriate under the parent protocol * Current treatment in another clinical study * Pregnant or breastfeeding * Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator, would make the subject inappropriate for entry into the study

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026